Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
31
IPA Quote, Financials, Valuation and Earnings
Last price:
$0.40
Seasonality move
:
-4.76%
Day range:
$0.40 - $0.44
52-week range:
$0.32 - $2.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.61x
P/B ratio:
0.53x
Volume:
192.4K
Avg. volume:
357K
1-year change:
-70.36%
Market cap:
$12.4M
Revenue:
$18.2M
EPS (TTM):
-$0.77
Analysts' Opinion
-
Consensus RatingImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, ImmunoPrecise Antibodies has an estimated upside of 1149.69% from its current price of $0.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.40.
Fair Value
-
According to the consensus of 0 analysts, ImmunoPrecise Antibodies has 1149.69% upside to fair value with a price target of -- per share.
IPA vs. S&P 500
-
Over the past 5 trading days, ImmunoPrecise Antibodies has overperformed the S&P 500 by 1.22% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ImmunoPrecise Antibodies does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ImmunoPrecise Antibodies revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter ImmunoPrecise Antibodies reported revenues of $4.5M.
Earnings Growth
-
ImmunoPrecise Antibodies has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ImmunoPrecise Antibodies reported earnings per share of -$0.07.
Enterprise value:
12.1M
EV / Invested capital:
0.47x
Price / LTM sales:
0.61x
EV / EBIT:
--
EV / Revenue:
0.68x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-1.82x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$8.9M
Return On Assets:
-41.65%
Net Income Margin (TTM):
-114.51%
Return On Equity:
-68.99%
Return On Invested Capital:
-67.12%
Operating Margin:
-46.03%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2023-10-31 | 2024-10-31 | |
| Income Statement | ||||||
| Revenue | $15.5M | $16.8M | $17.7M | $4.5M | $4.5M | |
| Gross Profit | $8.7M | $8.9M | $8.9M | $2.2M | $2.5M | |
| Operating Income | -$20.2M | -$10.8M | -$10.5M | -$2.1M | -$2.1M | |
| EBITDA | -$15.7M | -$7.6M | -$17.9M | -$907.7K | -$1.1M | |
| Diluted EPS | -$0.86 | -$0.47 | -$0.77 | -$0.07 | -$0.07 | |
| Period Ending | 2020-10-31 | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $18M | $35.5M | $16.7M | $11.1M | $9M | |
| Total Assets | $32.8M | $48.7M | $60.8M | $54.7M | $43.1M | |
| Current Liabilities | $5.9M | $6.1M | $5.4M | $5.4M | $8.9M | |
| Total Liabilities | $9.5M | $7.6M | $15.4M | $17M | $19.6M | |
| Total Equity | $23.3M | $41.1M | $45.4M | $37.6M | $23.5M | |
| Total Debt | $1.6M | $1M | -- | -- | $2.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2023-10-31 | 2024-10-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.1M | -$4.8M | -$5.7M | -$6.3K | -$1.6M | |
| Cash From Investing | -$4.8M | -$879.4K | -$1M | -$227.2K | -$48.2K | |
| Cash From Financing | $2.4M | -$1M | $4.8M | -$223.1K | $1.5M | |
| Free Cash Flow | -$17.3M | -$5.6M | -$6.7M | -$224.7K | -$1.7M | |
IPA
Sector
Market Cap
$12.4M
$44.6M
Price % of 52-Week High
15.39%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-22.81%
-0.68%
1-Year Price Total Return
-70.36%
-29.09%
Beta (5-Year)
0.210
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.41
200-day SMA
Sell
Level
$0.89
Bollinger Bands (100)
Sell
Level
0.42 - 0.74
Chaikin Money Flow
Buy
Level
18.1M
20-day SMA
Sell
Level
$0.40
Relative Strength Index (RSI14)
Sell
Level
45.86
ADX Line
Sell
Level
7.14
Williams %R
Neutral
Level
-62.0342
50-day SMA
Sell
Level
$0.45
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
116.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.371)
Sell
CA Score
(Annual)
Level (-1.4623)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (4.0947)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
Stock Forecast FAQ
In the current month, IPA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IPA average analyst price target in the past 3 months is --.
-
Where Will ImmunoPrecise Antibodies Stock Be In 1 Year?
According to analysts, the consensus estimate is that ImmunoPrecise Antibodies share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About ImmunoPrecise Antibodies?
Analysts are divided on their view about ImmunoPrecise Antibodies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ImmunoPrecise Antibodies is a Sell and believe this share price will drop from its current level to --.
-
What Is ImmunoPrecise Antibodies's Price Target?
The price target for ImmunoPrecise Antibodies over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IPA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ImmunoPrecise Antibodies is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IPA?
You can purchase shares of ImmunoPrecise Antibodies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ImmunoPrecise Antibodies shares.
-
What Is The ImmunoPrecise Antibodies Share Price Today?
ImmunoPrecise Antibodies was last trading at $0.40 per share. This represents the most recent stock quote for ImmunoPrecise Antibodies. Yesterday, ImmunoPrecise Antibodies closed at $0.40 per share.
-
How To Buy ImmunoPrecise Antibodies Stock Online?
In order to purchase ImmunoPrecise Antibodies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
